Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination

PHASE3CompletedINTERVENTIONAL

Enrollment

391

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

Postmenopause

Interventions

DRUG

continuous combined estradiol and dydrogesterone

0.5 Mg Estradiol and 2.5 Mg Dydrogesterone

DRUG

continuous combined estradiol and dydrogesterone

1 Mg Estradiol and 5 Mg Dydrogesterone

DRUG

Placebo

Trial Locations (18)

Site 11, Zagreb

Site 12, Zagreb

Site 13, Zagreb

Site 23, Cannes

Site 24, Cannes

Site 21, Montpellier

Site 22, Montpellier

Site 34, Katowice

Site 33, Krakow

Site 32, Lódź

Site 31, Warsaw

Site 41, Bucharest

Site 42, Bucharest

Site 44, Bucharest

Site 43, Craiova, Jud.Dolj

Site 51, Moscow

Site 52, Moscow

Site 53, Moscow

All Listed Sponsors

lead

Solvay Pharmaceuticals

INDUSTRY

NCT00251082 - Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination | Biotech Hunter | Biotech Hunter